Sanofi is trading 4.43% down at €69.86, with no confirmed company-specific news explaining the decline.
- Sanofi announced an expanded global alliance with Regeneron on October 1, covering next-generation, long-acting immunology antibodies; available coverage does not link it to the drop.
- Higher Treasury yields and pressure on European sentiment may offer broader market context, but available evidence does not establish them as the direct cause.
- Third-quarter results are scheduled for October 30.